You just read:

FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma

News provided by

Polaris Group

Mar 31, 2011, 08:00 ET